JP2019523249A - レボドパ及びカルビドパ腸管ゲル、並びに使用方法 - Google Patents

レボドパ及びカルビドパ腸管ゲル、並びに使用方法 Download PDF

Info

Publication number
JP2019523249A
JP2019523249A JP2019502047A JP2019502047A JP2019523249A JP 2019523249 A JP2019523249 A JP 2019523249A JP 2019502047 A JP2019502047 A JP 2019502047A JP 2019502047 A JP2019502047 A JP 2019502047A JP 2019523249 A JP2019523249 A JP 2019523249A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
active agent
carbidopa
levodopa
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019502047A
Other languages
English (en)
Japanese (ja)
Inventor
ディーク，アレクサンドル
ホワン，イエ
リパリ，ジョン・エム
ラグルズ，アレクサンダー
トゥン，スィン・ユイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc filed Critical AbbVie Inc
Publication of JP2019523249A publication Critical patent/JP2019523249A/ja
Priority to JP2022130386A priority Critical patent/JP2022166217A/ja
Priority to JP2024173125A priority patent/JP2025000924A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2019502047A 2016-07-20 2017-07-20 レボドパ及びカルビドパ腸管ゲル、並びに使用方法 Pending JP2019523249A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022130386A JP2022166217A (ja) 2016-07-20 2022-08-18 レボドパ及びカルビドパ腸管ゲル、並びに使用方法
JP2024173125A JP2025000924A (ja) 2016-07-20 2024-10-02 レボドパ及びカルビドパ腸管ゲル、並びに使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662364770P 2016-07-20 2016-07-20
US62/364,770 2016-07-20
PCT/US2017/043103 WO2018017850A1 (en) 2016-07-20 2017-07-20 Levodopa and carbidopa intestinal gel and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022130386A Division JP2022166217A (ja) 2016-07-20 2022-08-18 レボドパ及びカルビドパ腸管ゲル、並びに使用方法

Publications (1)

Publication Number Publication Date
JP2019523249A true JP2019523249A (ja) 2019-08-22

Family

ID=59506369

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019502047A Pending JP2019523249A (ja) 2016-07-20 2017-07-20 レボドパ及びカルビドパ腸管ゲル、並びに使用方法
JP2022130386A Ceased JP2022166217A (ja) 2016-07-20 2022-08-18 レボドパ及びカルビドパ腸管ゲル、並びに使用方法
JP2024173125A Pending JP2025000924A (ja) 2016-07-20 2024-10-02 レボドパ及びカルビドパ腸管ゲル、並びに使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022130386A Ceased JP2022166217A (ja) 2016-07-20 2022-08-18 レボドパ及びカルビドパ腸管ゲル、並びに使用方法
JP2024173125A Pending JP2025000924A (ja) 2016-07-20 2024-10-02 レボドパ及びカルビドパ腸管ゲル、並びに使用方法

Country Status (9)

Country Link
US (4) US20180021280A1 (https=)
EP (1) EP3487479A1 (https=)
JP (3) JP2019523249A (https=)
CN (1) CN109715139A (https=)
AU (2) AU2017299710A1 (https=)
BR (1) BR112019001082A2 (https=)
CA (1) CA3031254A1 (https=)
MX (2) MX2019000849A (https=)
WO (1) WO2018017850A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025039690A (ja) * 2019-08-30 2025-03-21 テルモ株式会社 注射液製剤

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016258179B2 (en) 2015-05-06 2021-07-01 Synagile Corporation Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use
US11844860B2 (en) 2018-03-02 2023-12-19 Chiesi Farmaceutici S.P.A. Pharmaceutical formulation for intraduodenal administration comprising melevodopa and carbidopa
EP4616878A1 (en) * 2024-03-15 2025-09-17 Cosmo Technologies Ltd. Cannula for rectal administration of an enema and compositions for use therewith

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08504764A (ja) * 1992-11-30 1996-05-21 ニストレム，クリスター 製薬学的製剤
JP2002516849A (ja) * 1998-06-03 2002-06-11 タロー・ファーマシューティカル・インダストリーズ・リミテッド 流出耐性医薬組成物
JP2009543761A (ja) * 2006-05-31 2009-12-10 ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング レボドパ／カルビドパの長期間２４時間腸内投与
WO2016036308A1 (en) * 2014-09-04 2016-03-10 Lobsor Pharmaceuticals Aktiebolag Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5831210B2 (ja) * 1973-04-09 1983-07-05 武田薬品工業株式会社 アンテイナスイセイケンダクエキノセイゾウホウ
CN1901881A (zh) * 2003-10-31 2007-01-24 阿尔扎公司 用于增强的吸收的组合物和剂型
DE102006034346B4 (de) * 2006-07-25 2008-11-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren und Vorrichtung zum periodischen Messen der Fließgrenze von Dispersionen sowie deren Verwendung
US20150182688A1 (en) * 2013-12-31 2015-07-02 Abbvie Inc. Devices and methods for delivering a beneficial agent to a user
SE538425C2 (en) * 2014-09-04 2016-06-21 Lobsor Pharmaceuticals Ab Pharmaceutical compositions comprising levodopa, carbidopa and a comt inhibitor and method of administration thereof
MA41377A (fr) * 2015-01-20 2017-11-28 Abbvie Inc Gel intestinal de lévodopa et de carbidona et procédés d'utilisation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08504764A (ja) * 1992-11-30 1996-05-21 ニストレム，クリスター 製薬学的製剤
JP2002516849A (ja) * 1998-06-03 2002-06-11 タロー・ファーマシューティカル・インダストリーズ・リミテッド 流出耐性医薬組成物
JP2009543761A (ja) * 2006-05-31 2009-12-10 ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング レボドパ／カルビドパの長期間２４時間腸内投与
WO2016036308A1 (en) * 2014-09-04 2016-03-10 Lobsor Pharmaceuticals Aktiebolag Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025039690A (ja) * 2019-08-30 2025-03-21 テルモ株式会社 注射液製剤
JP2025039691A (ja) * 2019-08-30 2025-03-21 テルモ株式会社 注射液製剤

Also Published As

Publication number Publication date
WO2018017850A1 (en) 2018-01-25
EP3487479A1 (en) 2019-05-29
JP2022166217A (ja) 2022-11-01
AU2017299710A1 (en) 2019-01-31
US20180021280A1 (en) 2018-01-25
JP2025000924A (ja) 2025-01-07
US20230129413A1 (en) 2023-04-27
BR112019001082A2 (pt) 2019-04-30
US20260014108A1 (en) 2026-01-15
CA3031254A1 (en) 2018-01-25
US20210059968A1 (en) 2021-03-04
MX2022014577A (es) 2023-01-11
CN109715139A (zh) 2019-05-03
MX2019000849A (es) 2019-09-13
AU2023203340A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
JP7232235B2 (ja) レボドパおよびカルビドパ経腸用ゲル剤ならびに使用方法
JP2025000924A (ja) レボドパ及びカルビドパ腸管ゲル、並びに使用方法
KR101152183B1 (ko) 도파민 아고니스트의 지속 방출을 위한 이식가능한 폴리머디바이스
CN1950069A (zh) 抗兴奋性神经毒性缓释眼内植入物及相关方法
WO2013144814A1 (en) Stable ready-to-use pharmaceutical composition of pemetrexed
JP2024129122A5 (https=)
CN1819820A (zh) 包含左甲状腺素钠的药物制剂
TW201902472A (zh) 含有艾瑞布林或其藥劑學上允許的鹽之注射劑
CN106963730A (zh) 高度稳定的奈帕芬胺眼用药物组合物
CN114668722A (zh) 一种盐酸西替利嗪喷雾剂及其制备方法
KR20250110202A (ko) 변형-방출 실로도신 조성물 및 남성 피임 방법에서 이의 용도

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200720

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210601

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210531

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211130

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220419